指南与共识慢性静脉疾病静脉血栓栓塞

髂静脉支架置入术后最佳抗血栓治疗原则(POATIVES):一项全国性专家德尔菲共识研究

Principles of Optimal Antithrombotic Therapy for Iliac VEnous Stenting (POATIVES): A national expert-based Delphi consensus study.
指南 / 共识 · J Vasc Surg Venous Lymphat Disord · 2024-01-18

该研究采用改良德尔菲法,由中国专家就非血栓性髂静脉病变、急性深静脉血栓形成和血栓后综合征三种场景下髂静脉支架置入后的抗血栓治疗形成共识。第一阶段问卷由283名受访者完成,第二阶段由28名血管外科医生和介入放射科医生组成的专家组对17条声明进行投票,其中关于抗血栓药物选择的多数声明获得高度共识。大多数声明可用于指导静脉支架置入后的抗血栓管理,但抗凝剂剂量和疗程、抗血小板药物的作用(尤其在非血栓性髂静脉病变患者中)等争议问题仍需进一步研究。

要点

  • 专家组就非血栓性髂静脉病变、急性深静脉血栓形成和血栓后综合征三种场景下静脉支架置入后的抗血栓治疗形成17条声明。
  • 关于抗血栓药物选择的多数声明获得高度共识。
  • 抗凝剂剂量和疗程、抗血小板药物的作用(尤其在非血栓性髂静脉病变患者中)仍需进一步研究。

核心结论

  • 基于中国专家关于髂静脉支架置入后三种常见场景抗血栓治疗的全国德尔菲共识,大多数声明可用于指导静脉支架置入后的抗血栓管理。
  • 抗凝剂剂量和疗程、抗血小板药物的作用(尤其在非血栓性髂静脉病变患者中)等争议问题仍需进一步研究。

研究设计与样本

  • 采用改良德尔菲法,通过两轮调查形成推荐共识。
  • 第一阶段问卷包含非血栓性髂静脉病变、急性深静脉血栓形成和血栓后综合征三种静脉支架置入临床场景,发送给中国各地的静脉从业者,由283名受访者完成。
  • 第二阶段由28名血管外科医生和介入放射科医生组成的专家组对17条声明进行投票,其中非血栓性髂静脉病变4条、深静脉血栓形成6条、血栓后综合征7条。

主要发现

  • 第一阶段问卷由283名受访者完成。
  • 第二阶段专家组由28名血管外科医生和介入放射科医生组成,对17条声明进行投票。
  • 关于抗血栓药物选择的多数声明获得高度共识。

关键数值与推荐

  • 专家组对17条声明进行投票:非血栓性髂静脉病变4条、深静脉血栓形成6条、血栓后综合征7条。
  • 关于抗血栓药物选择的多数声明获得高度共识。

临床怎么用

  • 大多数声明可用于指导静脉支架置入后的抗血栓管理。

局限性

  • 抗凝剂剂量和疗程、抗血小板药物的作用(尤其在非血栓性髂静脉病变患者中)等争议问题仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Management of antithrombotic therapy in patients undergoing venous stents has not yet reached consensus, and there are not any recommendations from published guidelines. We undertook a Delphi consensus from Chinese experts to develop recommendations regarding the preferred antithrombotic therapy in patients following venous stenting. METHODS: The phase 1 questionnaire was comprised of three clinical scenarios of venous stenting for non-thrombotic iliac vein lesions (NIVL), acute deep vein thrombosis (DVT), and post-thrombotic syndrome (PTS) and was sent to venous practitioners across China. In phase 2, the results of phase 1 were distributed to a panel of experts for evaluation along with a questionnaire encompassing a series of statements produced during phase 1. A modified Delphi method was used to reach consensus on recommendations through two rounds of surveys. RESULTS: The phase 1 questionnaire was completed by 283 respondents. In phase 2, an expert panel consisting of 28 vascular surgeons and interventional radiologists was assembled and voted 17 statements relating to antithrombotic management after venous stenting for NIVL (4 statements), DVT (6 statements), and PTS (7 statements). The majority of the statements about the antithrombotic agent selection received a high consensus strength. CONCLUSIONS: Based on the national Delphi consensus of Chinese experts regarding antithrombotic therapy following iliac venous stenting in three common scenarios, most of the statements could be used to guide antithrombotic management following venous stenting. Further studies are required to clarify controversial issues including the dose and duration of anticoagulants, the role of antiplatelet agents, especially in patients with NIVL.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Guo B, Chen C, Li Y, et al. Principles of Optimal Antithrombotic Therapy for Iliac VEnous Stenting (POATIVES): A national expert-based Delphi consensus study. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38242205. doi:10.1016/j.jvsv.2023.101739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。